



## CLAIMS

1. A compound selected from one of the following:



(1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-  
5-oxo-cyclopentaneheptanoic acid  
[RSS]




(1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-  
5-oxo-cyclopentaneheptanoic acid  
[RSR]


,

5 or a salt, solvate, chemically protected form or prodrug  
thereof.

2. (*trans*-2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-  
cyclopentaneheptanoic acid, of which at least 90% by weight  
10 is selected from one of the following forms:



(1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-  
5-oxo-cyclopentaneheptanoic acid  
[RSS]




(1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-  
5-oxo-cyclopentaneheptanoic acid  
[RSR]

or a salt, solvate, chemically protected form or prodrug  
thereof.


15

3. 2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-  
cyclopentaneheptanoic acid, of which at least 80% by weight

is in one of the following forms:



(1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-  
5-oxo-cyclopentaneheptanoic acid  
[RSS]



(1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-  
5-oxo-cyclopentaneheptanoic acid  
[RSR]

or a salt, solvate, chemically protected form or prodrug thereof.

5

4. A method of making a compound according to any one of claims 1 to 3.

5. A compound according to any one of claims 1 to 3, or a  
10 pharmaceutically acceptable salt thereof, for use in a  
method of therapy.

6. A pharmaceutical composition comprising a compound  
according to any one of claims 1 to 3, or a pharmaceutically  
15 acceptable salt thereof, together with a pharmaceutically  
acceptable carrier or diluent.

7. The use of a compound according to any one of claims 1  
to 3, or a pharmaceutically acceptable salt thereof in the  
20 preparation of a medicament for the treatment of a condition  
alleviated by agonism of an EP<sub>2</sub> receptor.

8. The use according to claim 7, wherein the condition  
alleviated by agonism of an EP<sub>2</sub> receptor is selected from  
25 the group consisting of: glaucoma, dysmenorrhoea and pre-  
term labour.

9. A method of treating a condition which can be alleviated by agonism of an EP<sub>2</sub> receptor, which method comprises administering to a patient in need of treatment an effective amount of a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof.

10. The method according to claim 9, wherein the condition alleviated by agonism of an EP<sub>2</sub> receptor is selected from the group consisting of: glaucoma, dysmenorrhoea and pre-term labour.

11. The use of an EP<sub>2</sub> receptor agonist, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of a condition alleviated by the inhibition of:

- (i) human T-cell activation (proliferation);
- (ii) the release of IL-2;
- 20 (iii) the release of TNF<sub>α</sub>; or
- (iv) the release of IFN<sub>γ</sub>.

12. The use of an EP<sub>2</sub> receptor agonist, or a pharmaceutically acceptable salt thereof in the preparation 25 of a medicament for the treatment of psoriasis.

13. The use of an EP<sub>2</sub> receptor agonist, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of inflammatory lung 30 diseases.

14. A use according to any one of claims 11 to 13, wherein the EP<sub>2</sub> receptor agonist is a compound of any one of claims 1 to 3.

15. A method of treating a condition which can be alleviated by the inhibition of:

- (i) human T-cell activation (proliferation);
- 5 (ii) the release of IL-2;
- (iii) the release of TNF<sub>α</sub>; or
- (iv) the release of IFN<sub>γ</sub>;

which method comprises administering to a patient in need of treatment an effective amount of an EP<sub>2</sub> receptor agonist, or  
10 a pharmaceutically acceptable salt thereof.

16. A method of treating a psoriasis, which method comprises administering to a patient in need of treatment an effective amount of an EP<sub>2</sub> receptor agonist, or a  
15 pharmaceutically acceptable salt thereof.

17. A method of treating an inflammatory lung disease, which method comprises administering to a patient in need of treatment an effective amount of an EP<sub>2</sub> receptor agonist, or  
20 a pharmaceutically acceptable salt thereof.

18. A method according to any one of claims 15 to 17, wherein the EP<sub>2</sub> receptor agonist is a compound of any one of claims 1 to 3.